America Handing MRNA Lead: Investors Reassess Biotech
A political shift in the United States is denting confidence in mRNA medicine, with funding drying up and manufacturi...
mRNA
2 articles
Here's Wouldn't Touch Moderna: Why I Won't Bet on Its Next Growth Engine
Moderna surged on pandemic-era demand. But what comes next? This piece examines why some investors are wary, what a t...